Appeals court temporarily keeps abortion pill on the market, but FDA may have to revert to older restrictions

Zachary Brennan

Senior Editor

The Fifth Circuit Court of Appeals late last night said the preterm birth drug mifepristone should remain on the market, at least temporarily, although changes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Appeals court temporarily keeps abortion pill on the market, but FDA may have to revert to older restrictions

Zachary Brennan

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

Ap­peals court tem­porar­i­ly keeps abor­tion pill on the mar­ket, but FDA may have to re­vert to old­er re­stric­tions

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Appeals court temporarily keeps abortion pill on the market, but FDA may have to revert to older restrictions

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena